enGene (NASDAQ: ENGN) is a late-stage biotechnology company mainstreaming genetic medicines through the delivery... are unresponsive to BCG. Detalimogene voraplasmid was developed using enGene's PROPRIETARY, Dually Derivatized Oligochitosan (DDX...
Lugar:
Boston, MA | 23/01/2026 20:01:20 PM | Salario: S/. No Especificado | Empresa:
enGeneenGene (NASDAQ: ENGN) is a late-stage biotechnology company, mainstreaming genetic medicines through the delivery... are unresponsive to BCG. Detalimogene voraplasmid was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX...
Lugar:
Boston, MA | 18/01/2026 01:01:25 AM | Salario: S/. No Especificado | Empresa:
enGeneenGene (NASDAQ: ENGN) is a late-stage biotechnology company mainstreaming genetic medicines through the delivery... are unresponsive to BCG. Detalimogene voraplasmid was developed using enGene's PROPRIETARY, Dually Derivatized Oligochitosan (DDX...
Lugar:
Boston, MA | 10/01/2026 20:01:32 PM | Salario: S/. $115000 - 135000 per year | Empresa:
enGene1